Single Strain

KB290

JUMP TO:
01
Summary

A single placebo-controlled, double-blind crossover trial involving 23 participants with IBS examined the effects of Lactobacillus brevis KB290.1 The study faced several limitations, including a high attrition rate, with over 34% of participants dropping out during the study period.

Results:

  • Bowel Movement Parameters: No significant differences were observed in bowel movement frequency, fecal volume and color, post-defecation physical sensations, or time taken for bowel movements across different study periods.
  • Stool Consistency: The study authors reported a significantly lower frequency of watery and mushy feces during the probiotic capsule consumption period compared to the pre-consumption observation period and the placebo period. However, independent calculations did not reveal a statistically significant difference in this change.
  • Quality of Life (QOL): No statistically significant differences were found in any QOL measures, including physical, emotional, social activities, pain, and overall health, among the study periods.

Key Takeaway: The evidence supporting Lactobacillus brevis KB290 is derived from a single crossover trial of suboptimal quality conducted in individuals with IBS. This trial does not indicate the superiority of this probiotic over placebo.

Recommended Dose: None at this time. Further research is needed.

 

 

Reference: 

  1. Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial.  Biopsychosoc Med 2012; 6: 16.  [doi: 10.1186/1751-0759-6-16]  S 
Read More…

A single placebo-controlled, double-blind crossover trial involving 23 participants with IBS examined the effects of Lactobacillus brevis KB290.1 The study faced several limitations, including a high attrition rate, with over 34% of participants dropping out during the study period.

Results:

  • Bowel Movement Parameters: No significant differences were observed in bowel movement frequency, fecal volume and color, post-defecation physical sensations, or time taken for bowel movements across different study periods.
  • Stool Consistency: The study authors reported a significantly lower frequency of watery and mushy feces during the probiotic capsule consumption period compared to the pre-consumption observation period and the placebo period. However, independent calculations did not reveal a statistically significant difference in this change.
  • Quality of Life (QOL): No statistically significant differences were found in any QOL measures, including physical, emotional, social activities, pain, and overall health, among the study periods.

Key Takeaway: The evidence supporting Lactobacillus brevis KB290 is derived from a single crossover trial of suboptimal quality conducted in individuals with IBS. This trial does not indicate the superiority of this probiotic over placebo.

Recommended Dose: None at this time. Further research is needed.

 

 

Reference: 

  1. Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial.  Biopsychosoc Med 2012; 6: 16.  [doi: 10.1186/1751-0759-6-16]  S 
Read More…
Find a probiotic with KB290

There is insufficient evidence demonstrating benefits for IBS with this probiotic. Therefore, we do not provide guidance on finding a commercial product containing this strain/blend.

A single placebo-controlled, double-blind crossover trial involving 23 participants with IBS examined the effects of Lactobacillus brevis KB290.1 The study faced several limitations, including a high attrition rate, with over 34% of participants dropping out during the study period.

Results:

  • Bowel Movement Parameters: No significant differences were observed in bowel movement frequency, fecal volume and color, post-defecation physical sensations, or time taken for bowel movements across different study periods.
  • Stool Consistency: The study authors reported a significantly lower frequency of watery and mushy feces during the probiotic capsule consumption period compared to the pre-consumption observation period and the placebo period. However, independent calculations did not reveal a statistically significant difference in this change.
  • Quality of Life (QOL): No statistically significant differences were found in any QOL measures, including physical, emotional, social activities, pain, and overall health, among the study periods.

Key Takeaway: The evidence supporting Lactobacillus brevis KB290 is derived from a single crossover trial of suboptimal quality conducted in individuals with IBS. This trial does not indicate the superiority of this probiotic over placebo.

Recommended Dose: None at this time. Further research is needed.

 

 

Reference: 

  1. Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial.  Biopsychosoc Med 2012; 6: 16.  [doi: 10.1186/1751-0759-6-16]  S 
02
Results
Overall evidence quality grade
60%

This probiotic has low to moderate quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial

    • 2012
    • Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T.

    • Biopsychosoc Med 2012; 6: 16

    • DOI: 10.1186/1751-0759-6-16
    • >/= 10 billion CFU
    • 4 week intervention
      4 week washout
      4 week placebo
    • Capsule
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED
      • CROSS-MATCHED

    • PEOPLE  >=6 years

    • ITT,PP (total) n=35,23
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • During the placebo consumption period, there was no significant difference compared to the washout period. However, during the test capsule consumption period, there was a notable decrease in the frequencies of watery and mushy feces compared to the pre-consumption observation period.

      • Despite these observations, our independent analysis found no statistically significant changes.

    • Constipation

      • No data

    • Bowel Habits

      • When examining bowel movement patterns, researchers looked at several factors, including the frequency of bowel movements, the volume and color of feces, the physical sensations experienced post-bowel movement, and the duration of the bowel movements.

      • Their findings revealed no significant differences across these variables during the different periods studied.

    • Global IBS Symptoms

      • No data

    • Abdominal Pain / Discomfort

      • No data

    • Bloating / Distention

      • No data

    • Gas / Flatulence

      • No data

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • Although no statistically significant difference was observed in any quality of life (QOL) items (including physical, emotional, social activities, pain, and overall health) among the study periods, it is worth noting that the mean score for all items decreased during the test capsule consumption period.

    • Miscellaneous Symptoms

      • No data

    • Notes

      • No data